About Us
Salathé Capital is a structured credit investment manager whose main focus is in the asset-backed securities market. Senior Leadership has over 40 years of combined experience and 10+ years working together.
​Salathé Capital was formed based on the idea that fixed income investors would greatly benefit from a new product that generates attractive returns and has low correlation to the traditional fixed income portfolio market. The question we asked ourselves was how can we bridge the gap between fixed-income investors and equity investors? What we developed was a fixed-income product that is unique in its ability to link equity returns to a rated fixed-income product, thus eliminating the gap between fixed-income and equity investors.
​
We believe traditional research, combined with leveraging the latest in technology, allows us to optimize return/risk characteristics of the underlying assets.
​
Salathé Capital believes that innovation, great people, and solid execution can transform fixed income investing.
David Sturgeon
Founder & CEO
Mr. David Sturgeon has 20+ years of experience across various asset management roles and industries. Over the course of his career, Mr. Sturgeon has managed structured product investment portfolios for a family office and a hedge fund before developing the CSN.
​
Mr. Sturgeon is the founder of Salathé Capital, an alternative asset management firm, where he oversees the day-to-day operations the firm. Prior to his role at Salathé Capital, LLC, Mr. Sturgeon was a portfolio manager for R&D Capital Partners, a hedge fund that focused on structured products. The goal of the investment strategy was to reduce downside risk while also allowing for participation in the upside of the equities and commodities markets. R&D Capital Partners was a finalist for S&P Cap IQ’s fixed income manager of the year award in 2014.
​
Prior to these roles, Mr. Sturgeon worked as a senior analyst for Capital Strategies Inc., a single-family office, where he was responsible for modeling and due diligence for structured products and fixed income. Prior to his role at Capital Strategies Inc., Mr. Sturgeon was an analyst at LandCo Equity Partners, a real estate investment firm where his responsibilities included financial modeling and deal structure modeling for real estate private equity transactions. Prior to LandCo, Mr. Sturgeon worked as an analyst at Arrowhead Investments where his duties included financial modeling and pitch book preparation, as well as meeting with investors and researching potential real estate private equity business opportunities.
​
Mr. Sturgeon earned a Masters of Science in Finance from The University of Denver. He is a graduate of the University of Northern Colorado, where he earned a BA in Management.
Dr. Richard Williams
Founding Investor & Senior Managing Partner
Dr. Richard Williams has managed, invested and consulted for more than 35 years in the start-up and development of 15 pre-public biotechnology companies. In this capacity he helped recruit management, focus business plans and raise initial capital while serving on the Boards of Directors. The most notable companies that into which Dr. Williams invested were Amgen, a major biotech firm, IGEN (acquired by Roche) and Supergen (acquired by Otsuka Pharma), all originally listed on NASDAQ stock exchange. For six years he was managing partner of Mara Venture Partners, LLC, an early-stage biotechnology venture capital fund with offices in Belgium and the US, and for 8 years served as an advisor to Vesalius Biocapital Fund, a private equity fund in the Benelux.
​
From 2002 to 2015, Dr. Williams served as a member of the Board of Trustees of Beacon College in Florida, the first higher education institution accredited to award bachelor degrees to students with learning differences and those on the autistic spectrum. He served as Chairman of the Board for 10 years.
​
From 1996 to 2003, Dr. Williams was a managing partner and chief analyst for an options trading firm that owned three seats on the Philadelphia Stock Exchange. Over a 6 year period, he served as director, acting CEO, and secretary-treasurer of ASM Resources, the venture capital arm of American Society of Microbiology. For 15 years ending 2018, he was a member of the Endowment Investment Committee of the American Society of Microbiology that managed a $110 million fund.
​
Prior to working with biotech companies, Dr. Williams spent 20 years teaching and researching in microbiology and infectious diseases in academia in European universities and in Africa with the WHO. He is author of 85 original peer-reviewed scientific publications.
Dr. Williams graduated with a BA and a PhD from the University of California at Berkeley. He also has a Master of Science in Finance from George Washington University in Washington DC.